Kyndryl Faces Class Action Over Financial Reporting Discrepancies

GlobeNewswire Inc.GlobeNewswire Inc.
|||1 min read
Key Takeaway

Kyndryl faces class action lawsuit alleging false financial statements and internal control weaknesses from August 2024 to February 2026, affecting investors who purchased securities during this period.

Kyndryl Faces Class Action Over Financial Reporting Discrepancies

A class action lawsuit has been filed against Kyndryl Holdings, Inc., alleging the company issued false and misleading statements regarding its financial position, internal controls, and ability to file quarterly reports on schedule. The litigation covers the period from August 7, 2024 through February 9, 2026, during which investors purchased company securities.

The lawsuit claims investors suffered damages based on material misrepresentations related to the company's financial reporting capabilities and internal control infrastructure. According to the filing, Kyndryl's statements during this window did not accurately reflect risks or weaknesses in its financial reporting processes.

Investors who purchased Kyndryl securities during the specified period are eligible to participate in the action. The deadline to apply for lead plaintiff status in the case is April 13, 2026, giving shareholders approximately two months to determine their involvement in the litigation.

Source: GlobeNewswire Inc.

Back to newsPublished Feb 23

Related Coverage

GlobeNewswire Inc.

Plug Power Faces Class Action Over DOE Loan Claims as April Deadline Looms

Plug Power faces class action lawsuit alleging false statements about DOE loans and hydrogen facilities. Investors have until April 3, 2026 to apply as lead plaintiffs.

PLUG
GlobeNewswire Inc.

BlackRock TCP Capital Hit by Class Action Over $19B NAV Collapse

BlackRock TCP Capital faces class action lawsuit after 19% NAV decline and 12.97% stock plunge. Investors must act by April 6 deadline.

TCPC
GlobeNewswire Inc.

Corcept Therapeutics Faces Class Action Over FDA Rejection; Stock Crashed 50%

Corcept Therapeutics faces securities fraud lawsuit after FDA rejected relacorilant application. Stock plummeted 50.4% following December rejection. Investor deadline April 21, 2026.

CORT
GlobeNewswire Inc.

Class Action Lawsuit Filed Against China Liberal Education Over Alleged $300M Pump-and-Dump Scheme

Class action lawsuit filed against China Liberal Education Holdings for alleged pump-and-dump scheme coordinating with scammers, resulting in $300M+ investor losses.

CLEUF
GlobeNewswire Inc.

METC Faces Class Action Over Brook Mine Claims; Lead Plaintiff Deadline Set for March 31

Ramaco Resources faces class action lawsuit over alleged false Brook Mine operational claims, with lead plaintiff deadline set for March 31, 2026.

METCMETCBMETCI
GlobeNewswire Inc.

Disc Medicine Stock Collapses on FDA Rejection; Law Firm Probes Securities Fraud

Pomerantz LLP investigates Disc Medicine ($IRON) for potential securities fraud after FDA rejected bitopertin drug application, triggering consecutive stock declines totaling over 28%.

IRON